UNSPSC 51162323: Acetaminophen/phenyltoloxamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51162323 Acetaminophen/phenyltoloxamine is a Commodity code that in practice encompasses a broader range of over-the-counter and generic pharmaceutical products than its narrow name suggests. State and local governments soliciting under this code are acquiring generic multi-source pharmaceuticals, OTC medications, and opioid-response products such as naloxone for public health and community health initiatives. Issuing bodies include county health departments, state procurement offices administering cooperative purchasing alliances, and multistate cooperative purchasing consortia. The scope reflects demand for pharmaceutical commodities with defined National Drug Codes (NDCs), specific strength and dosage forms, and established manufacturing compliance (cGMP, FDA certification, Drug Supply Chain Security Act compliance).

The most recent activity centers on Minnesota and Florida. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, extending across MMCAP member states including Oregon and other participants. Seminole County, Florida issued IFB 60459723LAS in June 2026 for naloxone and drug deactivation systems—1,900 units of naloxone and 800 safe drug deactivation systems annually—with quarterly deliveries required and a response deadline of July 26, 2023. The MMCAP procurement emphasizes pricing competitiveness (75 percent of evaluation weight), wholesaler-authorized distribution through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., and compliance with comprehensive insurance and supply-chain security standards. Both opportunities require vendor compliance with E-Verify, workers' compensation, and commercial general liability coverage.